#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cholangitis sclerosing Extra-osseous Ewing's sarcoma metastatic Gastrooesophageal cancer Hairy cell leukaemia recurrent Arrhythmia Germ cell cancer Philadelphia positive acute lymphocytic leukaemia Leber's congenital amaurosis Conjunctivitis allergic Autoimmune haemolytic anaemia Autoimmune myositis Myocarditis Cardiac arrest Fallopian tube cancer Usher's syndrome More trials…

    Learn about Rare Diseases

    Acute respiratory distress syndrome – Life with Disease Haemolytic uraemic syndrome – Diagnostics Hereditary angioedema with C1 esterase inhibitor deficiency – Diagnostics Congenital generalised lipodystrophy – Life with Disease Waldenstrom’s macroglobulinaemia refractory – Diagnostics Mucopolysaccharidosis I – Basic Information Rhabdoid tumour – Trials in Disease Pelizaeus-Merzbacher disease – Trials in Disease Isodicentric chromosome 15 syndrome – Life with Disease Pemphigus – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Elvn-002-1 Rbl012.2 Ubamatamab Amisulpride Motixafortide ATIRMOCICLIB Ixazomib Bepranemab Cefotaxime Selgantolimod Tetracaine Hydrochloride Pimecrolimus Lapatinib Cabergoline Azd5863 Perflubutane Posenacaftor SALICYLIC ACID Amiloride Hydrochloride Nortriptyline Hydrochloride More therapies…

    Learn about Your Condition

    Death neonatal Hepatocellular carcinoma Bladder cancer recurrent Angiopathy Bile acid synthesis disorder Sjogren's syndrome Complex regional pain syndrome Idiopathic pulmonary fibrosis Leukaemia Myasthenia gravis Incontinence Tumour thrombosis Ventricular fibrillation Angelman's syndrome Foetal growth restriction More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Theageneio Cancer Hospital

Theageneio Cancer Hospital

Simeonidi Alex 2, Thessaloniki, 546 39, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

    Recruiting

    3 1 1
    Investigated Diseases:
    • Gastrointestinal stromal tumour
    Investigated Drugs:
    • [4-(METHYL-1H-PYRAZOL-4-YL)-BENZYL]-(6[7-(3-PYRROLIDIN-1-YL-PROPOXY)-IMIDAZO[1,2-A]PYRIDIN-3-YL]-PYRIMIDIN-4-YL]-AMINE
    • Imatinib Mesilate
    Finland France Germany Greece Hungary Italy +7

  • Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

    Recruiting

    2 1 1
    Investigated Drugs:
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    • Human Normal Immunoglobulin (Iv)
    • Tocilizumab
    France Greece Hungary Portugal Spain Sweden

  • Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Adagrasib
    • Cetuximab
    • Dexamethasone
    Belgium France Germany Greece Hungary Italy +5

  • Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Cevostamab
    • Carfilzomib
    • Daratumumab
    Czechia Denmark France Germany Greece Italy +2

  • Study of telisotuzumab adizutecan plus drug combination in adults with refractory metastatic colorectal cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Colorectal cancer
    Investigated Drugs:
    • Bevacizumab
    • Tipiracil
    • Trifluridine
    Belgium Germany Greece Portugal Spain

  • EIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Pembrolizumab
    • Resiquimod Sulfate
    Austria Belgium Bulgaria France Germany Greece +6

  • JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

    Recruiting

    3 1 1
    Investigated Drugs:
    • IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL RECEPTOR CD3, B-CELL MATURATION ANTIGEN AND G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D
    • Teclistamab
    France Germany Greece Italy The Netherlands Norway +1

  • Study of belantamab mafodotin with drug combination in adults aged 18 years and older with relapsed or refractory multiple myeloma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma refractory
    Investigated Drugs:
    • Belantamab Mafodotin
    • Bortezomib
    • Carfilzomib
    France Germany Greece The Netherlands Spain

  • Comparing Sotorasib and Pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Hydroxocobalamin
    • Sotorasib
    • Betamethasone Sodium Phosphate Ph. Eur
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • ICOTROKINRA
    Belgium Czechia France Germany Greece Hungary +7
1 2 3 … 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!